Literature DB >> 28100625

The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7.

Anita Szalmás1,2, Vjekoslav Tomaić3,4, Om Basukala3, Paola Massimi3, Suruchi Mittal3, József Kónya2, Lawrence Banks3.   

Abstract

Activation of signaling pathways ensuring cell growth is essential for the proliferative competence of human papillomavirus (HPV)-infected cells. Tyrosine kinases and phosphatases are key regulators of cellular growth control pathways. A recently identified potential cellular target of HPV E7 is the cytoplasmic protein tyrosine phosphatase PTPN14, which is a potential tumor suppressor and is linked to the control of the Hippo and Wnt/beta-catenin signaling pathways. In this study, we show that the E7 proteins of both high-risk and low-risk mucosal HPV types can interact with PTPN14. This interaction is independent of retinoblastoma protein (pRb) and involves residues in the carboxy-terminal region of E7. We also show that high-risk E7 induces proteasome-mediated degradation of PTPN14 in cells derived from cervical tumors. This degradation appears to be independent of cullin-1 or cullin-2 but most likely involves the UBR4/p600 ubiquitin ligase. The degree to which E7 downregulates PTPN14 would suggest that this interaction is important for the viral life cycle and potentially also for the development of malignancy. In support of this we find that overexpression of PTPN14 decreases the ability of HPV-16 E7 to cooperate with activated EJ-ras in primary cell transformation assays.IMPORTANCE This study links HPV E7 to the deregulation of protein tyrosine phosphatase signaling pathways. PTPN14 is classified as a potential tumor suppressor protein, and here we show that it is very susceptible to HPV E7-induced proteasome-mediated degradation. Intriguingly, this appears to use a mechanism that is different from that employed by E7 to target pRb. Therefore, this study has important implications for our understanding of the molecular basis for E7 function and also sheds important light on the potential role of PTPN14 as a tumor suppressor.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  E7; PTPN14; human papillomavirus; transformation; tyrosine phosphatases

Mesh:

Substances:

Year:  2017        PMID: 28100625      PMCID: PMC5355602          DOI: 10.1128/JVI.00057-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses.

Authors:  David Pim; Lawrence Banks
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

Review 2.  FERM family proteins and their importance in cellular movements and wound healing (review).

Authors:  David C Bosanquet; Lin Ye; Keith G Harding; Wen G Jiang
Journal:  Int J Mol Med       Date:  2014-05-08       Impact factor: 4.101

3.  Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes.

Authors:  N Sanjib Banerjee; Nicholas J Genovese; Francisco Noya; Wei-Ming Chien; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation.

Authors:  Bjørn I Bertelsen; Solrun J Steine; Roar Sandvei; Anders Molven; Ole Didrik Laerum
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

5.  The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.

Authors:  Kwang-Jin Oh; Anna Kalinina; Jing Wang; Keiko Nakayama; Keiichi I Nakayama; Srilata Bagchi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 6.  Papillomaviruses in the causation of human cancers - a brief historical account.

Authors:  Harald zur Hausen
Journal:  Virology       Date:  2009-01-08       Impact factor: 3.616

7.  Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor.

Authors:  KyungWon Huh; Xiaobo Zhou; Hiroyuki Hayakawa; Je-Yoel Cho; Towia A Libermann; Jianping Jin; J Wade Harper; Karl Munger
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

8.  Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein.

Authors:  Craig W Menges; Laurel A Baglia; Randi Lapoint; Dennis J McCance
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 13.312

Review 9.  Role of human papillomaviruses in carcinogenesis.

Authors:  Raffaella Ghittoni; Rosita Accardi; Susanna Chiocca; Massimo Tommasino
Journal:  Ecancermedicalscience       Date:  2015-04-29

10.  The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner.

Authors:  S T Charette; D J McCance
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 8.756

View more
  22 in total

1.  Exploring drivers of gene expression in the Cancer Genome Atlas.

Authors:  Andrea Rau; Michael Flister; Hallgeir Rui; Paul L Auer
Journal:  Bioinformatics       Date:  2019-01-01       Impact factor: 6.937

2.  The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.

Authors:  Jayashree Thatte; Paola Massimi; Miranda Thomas; Siaw Shi Boon; Lawrence Banks
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

3.  Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.

Authors:  Marcel Chris Conrady; Irina Suarez; Gergö Gogl; Desiree Isabella Frecot; Anna Bonhoure; Camille Kostmann; Alexandra Cousido-Siah; André Mitschler; JiaWen Lim; Murielle Masson; Thomas Iftner; Frank Stubenrauch; Gilles Travé; Claudia Simon
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

4.  PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.

Authors:  Nathaniel Edward Bennett Saidu; Vedrana Filić; Miranda Thomas; Vanessa Sarabia-Vega; Anamaria Đukić; Frane Miljković; Lawrence Banks; Vjekoslav Tomaić
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

5.  A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.

Authors:  Joshua Hatterschide; Alexis C Brantly; Miranda Grace; Karl Munger; Elizabeth A White
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

6.  Regulation of HPV E7 Stability by E6-Associated Protein (E6AP).

Authors:  Arushi Vats; Oscar Trejo-Cerro; Paola Massimi; Lawrence Banks
Journal:  J Virol       Date:  2022-08-02       Impact factor: 6.549

7.  Human Papillomavirus E6 interaction with cellular PDZ domain proteins modulates YAP nuclear localization.

Authors:  Sydney Webb Strickland; Nicole Brimer; Charles Lyons; Scott B Vande Pol
Journal:  Virology       Date:  2018-01-12       Impact factor: 3.616

8.  PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.

Authors:  Joshua Hatterschide; Amelia E Bohidar; Miranda Grace; Tara J Nulton; Hee Won Kim; Brad Windle; Iain M Morgan; Karl Munger; Elizabeth A White
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-20       Impact factor: 11.205

Review 9.  The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation.

Authors:  James A Scarth; Molly R Patterson; Ethan L Morgan; Andrew Macdonald
Journal:  J Gen Virol       Date:  2021-01-11       Impact factor: 3.891

10.  Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation.

Authors:  Joseph A Westrich; Cody J Warren; Michael J Klausner; Kejun Guo; Chang-Wei Liu; Mario L Santiago; Dohun Pyeon
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.